Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. reports developments in its biopharmaceutical royalty aggregation and technology-licensing business. The company partners with pharmaceutical and biotechnology companies, funds late-stage clinical development programs in exchange for long-term economic interests, and manages royalty interests across development- and commercial-stage therapeutic assets.
Recurring LGND news includes operating and financial results, royalty revenue drivers, material agreements, capital-structure updates, and partner clinical or regulatory events tied to products in the portfolio. Company updates also cover proprietary technologies such as Captisol® and NITRICIL™, business-development activity, and portfolio assets such as FILSPARI® where Ligand has an economic interest.
Ligand Pharmaceuticals (Nasdaq: LGND) has completed its merger between subsidiary LNHC, Inc. and Channel Therapeutics' subsidiary CHRO Merger Sub Inc. The combined entity, Pelthos Therapeutics, will trade on NYSE American under ticker "PTHS" starting July 2, 2025.
Concurrent with the merger, Pelthos raised $50.1 million in equity capital, with $32 million from the Murchinson-led investor group and $18 million from Ligand. The company is preparing to launch ZELSUVMI™, an FDA-designated novel drug for Molluscum contagiosum infections, in July 2025. Ligand will receive a 13% royalty on worldwide ZELSUVMI sales.
ZELSUVMI is the first home-administered prescription treatment for molluscum, a condition affecting an estimated 16.7 million people in the US. Pelthos will also evaluate Channel's NaV 1.7 programs for various pain treatments.
Ligand Pharmaceuticals (LGND) has announced it will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis, along with senior management and board members, will participate in the ceremony to celebrate recent company milestones, including two value-creating transactions.
Davis highlighted Ligand's transformation into a profitable, infrastructure-light organization that focuses on acquiring and generating royalties from a diverse biopharmaceutical product portfolio. The company aims to continue building on its two-year momentum, supporting partner development of breakthrough medicines, and creating long-term shareholder value. The ceremony will be broadcast live at 9:15 a.m. Eastern Time.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its senior management team's participation in three upcoming investor conferences in May 2025:
- H.C. Wainwright Royalty Company Conference (Virtual) - Fireside chat on May 13 at 3:30 p.m. ET
- RBC Capital Markets Global Healthcare Conference (New York) - Fireside chat on May 20 at 2:05 p.m. ET
- Craig-Hallum Institutional Investor Conference (Minneapolis) - One-on-one meetings on May 28
Management will be available for one-on-one meetings with investors during all conferences. Interested investors should contact their respective conference representatives to arrange meetings.
Ligand Pharmaceuticals (Nasdaq: LGND) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
The conference call will be accessible via phone at (800) 715-9871 for U.S. & Canada callers and (646) 307-1963 for international participants, using Conference ID 3661098. A live webcast and replay of the call will also be available.
Ligand Pharmaceuticals (NASDAQ: LGND) announced a merger agreement to combine its subsidiary Pelthos Therapeutics with Channel Therapeutics (NYSE: CHRO). The transaction, expected to close in summer 2025, will raise $50 million in equity capital, with Ligand investing $18 million and an investor group led by Murchinson contributing $32 million.
The combined company will operate as Pelthos Therapeutics Inc. (NYSE: PTHS) and focus on commercializing ZELSUVMI™, an FDA-approved prescription medication for Molluscum contagiosum infections. ZELSUVMI is the first home-use treatment approved for patients aged one year and older. Ligand will retain a 13% royalty on worldwide sales.
The merged entity will maintain Channel's NaV 1.7 development programs for chronic pain, eye pain, and post-surgical nerve blocks. Scott Plesha will serve as CEO of the combined company, with Frank Knuettel II as CFO.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in two major healthcare investor conferences this March 2025. CEO Todd Davis and CFO Tavo Espinoza will represent the company at both events in Miami.
The management team will attend the Leerink Partners Global Healthcare Conference on March 10, engaging in one-on-one meetings with investors. Following this, they will participate in the Barclays 27th Annual Global Healthcare Conference on March 12, where they will join a fireside chat at 12:00 p.m. ET and conduct additional one-on-one meetings.
Investors interested in scheduling individual meetings with Ligand's management should reach out to their Leerink or Barclays representatives to arrange appointments.
Ligand Pharmaceuticals (LGND) reported strong financial results for Q4 and full year 2024, with total revenues reaching $167.1 million for the year. The company saw a 28% growth in royalty revenue, driven by strong performance across major commercial programs.
Q4 2024 revenues were $42.8 million, up 52% from Q4 2023, primarily due to royalty revenue of $34.8 million. However, LGND reported a Q4 GAAP net loss of $31.1 million ($1.64 per share), compared to net income of $18.2 million in Q4 2023.
Key highlights include FDA approvals for three portfolio products with blockbuster potential: Verona's Ohtuvayre, Travere's Filspari, and Merck's Capvaxive. The company reiterated its 2025 guidance of $180-$200 million in revenues and adjusted earnings per share of $6.00-$6.25.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced a $75 million royalty financing agreement with Castle Creek Biosciences to support the Phase 3 clinical study of D-Fi (FCX-007), an autologous gene-modified cell therapy for dystrophic epidermolysis bullosa (DEB). Ligand invested $50 million, leading a syndicate of co-investors who contributed $25 million, in exchange for a high-single digit royalty on worldwide sales of D-Fi. The syndicate includes Paragon Biosciences, Valor Equity Partners, and XOMA Royalty (Nasdaq: XOMA).
D-Fi, an injectable therapy, addresses DEB, a rare genetic skin disorder caused by a mutation in the COL7A1 gene. The therapy uses genetically modified dermal fibroblasts to express COL7 protein, aiding the formation of skin anchoring fibrils. Clinical studies have shown D-Fi to be generally well tolerated, with injection site reactions being the primary adverse effects.
D-Fi has received multiple FDA designations, including Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).